Bulletin
Investor Alert

Syros Pharmaceuticals Inc.

NAS: SYRS

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Syros Pharmaceuticals Inc.

After Hours

 --Quotes are delayed by 20 min

Mar 30, 2023, 6:54 p.m.

SYRS
/zigman2/quotes/201168308/composite

$

2.85

Change

+0.13 +4.78%

Volume

Volume 97

Quotes are delayed by 20 min

/zigman2/quotes/201168308/composite

Today's close

$ 2.79

$ 2.72

Change

-0.07 -2.51%

Day low

Day high

$2.68

$2.84

Open

52 week low

52 week high

$2.67

$13.20

Open

Company Description

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cam...

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Valuation

Price to Sales Ratio

3.05

Price to Book Ratio

0.57

Enterprise Value to EBITDA

0.68

Enterprise Value to Sales

-5.64

Total Debt to Enterprise Value

-0.68

Efficiency

Revenue/Employee

127,179.00

Income Per Employee

-809,009.00

Receivables Turnover

6.37

Total Asset Turnover

0.07

Liquidity

Current Ratio

6.87

Quick Ratio

6.87

Cash Ratio

6.57

Profitability

Gross Margin

80.06

Operating Margin

-849.21

Pretax Margin

-636.12

Net Margin

-636.12

Return on Assets

-44.29

Return on Equity

-88.90

Return on Total Capital

-73.96

Return on Invested Capital

-56.07

Capital Structure

Total Debt to Total Equity

49.77

Total Debt to Total Capital

33.23

Total Debt to Total Assets

26.00

Long-Term Debt to Equity

48.15

Long-Term Debt to Total Capital

32.15

Officers and Executives

Name Age Officer Since Title
Dr. Nancy A. Simonian 60 2012 President, CEO, Chief Financial Officer & Director
Mr. Jason Haas 54 2021 Chief Financial Officer
Dr. Eric R. Olson 63 2013 Chief Scientific Officer
Dr. David A. Roth 58 2015 Chief Medical Officer
Ms. Kristin Stephen - - Senior Vice President-Product

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
04/01/2022 Nancy A. Simonian
President & CEO; Director 		58,883   Derivative/Non-derivative trans. at $1.12 per share. 65,948
04/01/2022 Kristin Stephens
Chief Development Officer 		14,115   Derivative/Non-derivative trans. at $1.12 per share. 15,808
04/01/2022 Eric R. Olson
Chief Scientific Officer 		27,266   Derivative/Non-derivative trans. at $1.12 per share. 30,537
04/01/2022 David A. Roth
Chief Medical Officer 		27,281   Derivative/Non-derivative trans. at $1.12 per share. 30,554
01/05/2022 Eric R. Olson
Chief Scientific Officer 		2,208   Disposition at $3.47 per share. 7,661
07/01/2021 Eric R. Olson
Chief Scientific Officer 		1,164   Disposition at $5.55 per share. 6,460
03/15/2021 Eric R. Olson
Chief Scientific Officer 		3,628   Disposition at $9.47 per share. 34,357
03/15/2021 Eric R. Olson
Chief Scientific Officer 		3,628   Derivative/Non-derivative trans. at $1.01 per share. 3,664
02/16/2021 Richard A. Young
Director 		3,750   Disposition at $12.05 per share. 45,187
02/08/2021 Richard A. Young
Director 		3,750   Disposition at $13.04 per share. 48,900
12/18/2020 Nancy A. Simonian
President & CEO; Director 		4,988   Derivative/Non-derivative trans. at $10.09 per share. 50,328
12/18/2020 Nancy A. Simonian
President & CEO; Director 		14,168   Derivative/Non-derivative trans. at $8.51 per share. 120,569
12/18/2020 Nancy A. Simonian
President & CEO; Director 		10,761   Derivative/Non-derivative trans. at $3.04 per share. 32,713
12/08/2020 Samsara Biocapital LLC
Director 		625,000   Award at $0 per share. 0
11/17/2020 Richard A. Young
Director 		5,357   Disposition at $8.75 per share. 46,873
11/17/2020 Richard A. Young
Director 		5,357   Disposition at $8.75 per share. 46,873
11/16/2020 Richard A. Young
Director 		633   Disposition at $8.98 per share. 5,684
11/16/2020 Richard A. Young
Director 		633   Disposition at $8.98 per share. 5,684
/news/latest/company/us/syrs

MarketWatch News on SYRS

  1. Syros Pharmaceuticals stock price target cut to $10 from $14 at Alliance Global

    5:59 a.m. May 17, 2022

    - Tomi Kilgore

  2. Syros Pharmaceuticals stock price target cut to $8 from $10 at Wedbush

    8:18 a.m. Dec. 7, 2020

    - Tomi Kilgore

  3. Syros Pharmaceuticals downgraded to neutral from outperform at Wedbush

    9:27 a.m. Jan. 17, 2020

    - Tomi Kilgore

  5. Syros Pharmaceuticals started at outperform with $18 stock price target at Wedbush Securities

    7:24 a.m. July 25, 2016

    - Tomi Kilgore

  6. Syros Pharmaceuticals sets IPO price expectations

    7:44 a.m. June 20, 2016

    - Tomi Kilgore

  7. Syros Pharmaceuticalsto offer 4 mln shares in its IPO

    7:32 a.m. June 20, 2016

    - Tomi Kilgore

  8. Syros Pharmaceuticals expects IPO price of between $14 and $16 a share

    7:31 a.m. June 20, 2016

    - Tomi Kilgore

/news/nonmarketwatch/company/us/syrs

Other News on SYRS

  1. 10-K: SYROS PHARMACEUTICALS, INC.

    8:17 a.m. March 2, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. Top 5 4th Quarter Trades of ADAGE CAPITAL PARTNERS GP, L.L.C.

    11:00 p.m. Feb. 17, 2023

    - GuruFocus.com

  5. 10-Q: SYROS PHARMACEUTICALS, INC.

    8:20 a.m. Nov. 14, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  6. Syros Pharmaceuticals Q3 2022 Earnings Preview

    1:20 p.m. Nov. 11, 2022

    - Seeking Alpha

  7. Notable earnings before Monday's open

    10:23 a.m. Nov. 11, 2022

    - Seeking Alpha

  13. Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders

    6:45 a.m. Sept. 20, 2022

    - Seeking Alpha

  14. AVCT, MSC and VTAQ among mid-day movers

    1:06 p.m. Sept. 19, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Syros Pharmaceuticals, Inc.

35 CambridgePark Drive

4th floor

Cambridge, Massachusetts 02140-2325

Phone

1 6177441340

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

View SEC Filings

Revenue

$14.88M

Net Income

$-94.65M

Employees

117.00

Annual Report for SYRS

/news/pressrelease/company/us/syrs

Press Releases on SYRS

  2. Syros to Participate in Upcoming Investor Conferences in March

    8:30 a.m. Feb. 28, 2023

    - BusinessWire - BZX

  4. Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    5:05 p.m. Feb. 9, 2023

    - BusinessWire - BZX

  6. Syros Announces Clinical Updates and 2023 Strategic Priorities

    8:00 a.m. Jan. 9, 2023

    - BusinessWire - BZX

  7. Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    5:05 p.m. Dec. 23, 2022

    - BusinessWire - BZX

  15. Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    4:30 p.m. Nov. 4, 2022

    - BusinessWire - BZX

  17. Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    4:01 p.m. Oct. 5, 2022

    - BusinessWire - BZX

  21. Loading more headlines...
Link to MarketWatch's Slice.